Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00122304 · ClinicalTrials.gov registry record · Phase 3
Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab
A Phase 3 study, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 85
- Enrollment target
NCT00122304 is a Phase 3 study that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 85 participants.
The verdict
NCT00122304, a Phase 3 study, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 85 participants
- Enrollment target
Study Summary
The primary objective is to evaluate the safety of eculizumab in patients with transfusion-dependent hemolytic PNH
Interventions
- DRUG eculizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2004-12 |
| Est. Completion | 2006-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00122304
The ClinicalTrials.gov registry entry for NCT00122304 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which eculizumab is the first listed.
NCT00122304 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00122304 about?
NCT00122304 is a clinical study titled "Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab". The primary objective is to evaluate the safety of eculizumab in patients with transfusion-dependent hemolytic PNH
What is the current status of trial NCT00122304?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 85 participants. The study started on 2004-12. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00122304?
The interventions under investigation include: eculizumab (DRUG).
Who is sponsoring clinical trial NCT00122304?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.